Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new system is proposed for treating the spectrum of patients with high blood pressure. It is based on studies of the renin axis using renin profiling, pharmacologic probes and our bipolar vasoconstriction-volume hypothesis. The new system does not require renin profiling, pharmacologic testing or a vasoconstriction-volume analysis for widespread application. But these procedures, whenever available, will make treatment more efficient and more certain, and at the same time provide better base line definition. In the new system, all patients, except the elderly and those with congestive heart failure, bradycardia or a history of asthma, are treated first with propranolol alone, a procedure which will diminish or normalize blood pressure in many patients with high and noraml renin levels. For nonresponders, diuretic therapy is then superimposed. Subsequently, a propranolol subtraction trial picks out the low-renin patients who will usually respond to a diuretic alone. This program is likely to be fully effective in possible up to 85 per cent of patients. For the residual smaller fraction, drugs such as hydralazine, methyl DOPA, clonidine, reserpine or guanethidine are then added in traditional trial and error fashion. The proposed system has the theoretic attraction for long-term commitment, implicit in antihypertensive therapy, of achieving blood pressure control in large fractions with one drug instead of two or with two drugs instead of three or more. Moreover, the large groups who respond to therapy with propranolol alone (most high-renin and normal-renin patients) or to diuretics alone (most low-renin patients) gain the advantage of simple, more specific, long-term (i.e., antirenin or antivolume) therapy. The use of propranolol alone has practical and theoretic advantages over diuretics. Control may be achieved with even fewer side effects and without hypokalemia and chronic dehydration with its possibly adverse consequences (hyperuricemia, azotemia, hyperlipidemia, hyperreninemia, increased blood viscosity). Also, propranolol provides more direct control of the increased peripheral resistance and of neurogenically-induced swings in blood pressure. At the same time, the new system efficiently exploits the long-term use of diuretic therapy alone in low-renin patients in whom volume excess seems a causal factor. And it tends to avoid the use of diuretics in high-renin patients and of beta-blockers in low-renin patients in whom these drug types may be contraindicated.
 ...
PMID:Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. 1 Jul 30

Excretion of catecholamines and DOPA was impaired in patients with metabolic-alimentary obesity, with ischemic disease of heart, with atherosclerosis and excessive weight. Distinct decrease in content of adrenaline, noradrenaline and DOPA was observed in patients with obesity; the phenomenon was less pronounced in ischemic disease of heart, mainly in aged patients. Correlation was found between the rate of excretion of catecholamines and DOPA and the extent of hyperlipidemia. Dietetics did not normalize completely the impairments studied. Additional administration of pyridoxine caused a favorable effect.
 ...
PMID:[Excretion of catecholamines and DOPA in lipid metabolism disorders]. 59 86

In patients with ischemic heart disease (IHD) with excess body weight the excretion of catecholamines and DOPA was investigated. In patients of middle and advanced age the excretion of norepinephrine was found to be down, while in those of the young age the excretion of epinephrine and norepinephrine proved to be up. There exist a correlation between the rising level of norepinephrine and hyperlipidemia. In patients with IHD the blood serotonin content is elevated. The use of an antiatherosclerotic diet with a higher protein content tends to bring down the level of the norepinephrine and, partially, also of epinephrine excretion. With patients kept on an antiatherosclerotic diet with protein content the excretion of norepinephrine sharply decreases and that of epinephrine rises. Administration of pyridoxine superimposed upon dietary variants acts favorably on the catecholamines excretion. Under the effect of the diets in question the blood serotonin remains unchanged. The implication is that both the high- and low-protein quotas in the composition of antiatherosclerotic diets do not produce an optimal effect on the catecholamines and DOPA metabolism in patients with IHD and an excess body weight.
 ...
PMID:[Effect of an anti-atherosclerotic diet with different protein content on catecholamine and DOPA excretion in patients with ischemic heart disease and excess weight]. 88 10

The effect of body weight excess and hyperlipidemia on stimulated growth hormone (GH) secretion and serum somatomedin activity (SSA) has been investigated. Among 40 obese men gradually impairment of GH secretory response during the insulin hypoglycemia test was shown. Propranolol-L-DOPA administration elicited satisfactory GH secretory response only in the subgroup of patients with the mild weight excess. SSA was found to be in the normal range among the whole group of obese patients, however, it was significantly depressed in subjects with average weight excess higher than 100%. Obese men with hypertriglyceridemia and hypercholesterolemia presented low SSA even when their weight excess was relatively moderate, i.e., 52% and 57%, respectively.
 ...
PMID:Serum somatomedin activity and growth hormone level in obese men: dependence on degree of obesity and hyperlipidemia. 355 17

L-DOPA, which is a metabolic precursor of catecholamines, reduced the manifestations of hyperlipidemia developed in animals after administration of Triton WR-1339, dexametasone or cholesterol. At the same time, L-DOPA decreased the rate of lipolysis, induced by adrenaline injection, as well as the content of 11-hydrocorticosteroids in blood plasma.
 ...
PMID:[Effect of L-dopa on some patterns of lipid metabolism in experimental animals]. 728 65

The combination of Parkinson syndrome (PS) and prolonged visually evoked potentials (VEPs) in a single patient with hepatic encephalopathy (HE) has not been reported. A 52-year-old male with chronic HE developed PS in early 2001. Treatment with L-DOPA was only of minimal effect. In August 2001 he was admitted because of worsening PS and HE. There was anemia, hyperlipidaemia, markedly elevated liver-function-parameters, hyperammonemia, elevated resting-lactate, steatosis hepatis and hepatomegalia. VEPs showed markedly prolonged P100-latencies. Under L-DOPA, pramipexol, L-ornithin-L-aspartate, paromomycin-sulfate, and lactulose liver-function-parameters normalized and PS markedly improved. In February 2003, VEPs were normal. L-DOPA was discontinued by the patient in April 2003 and pramipexol in December 2003. Since then PS did not recur. This case shows that HE may go along with reversible PS and prolonged VEPs. Under adequate therapy liver-function-parameters and VEPs normalize and PS disappears.
 ...
PMID:Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy. 1591 50